Skip to main content
NASDAQ:SAVA

Cassava Sciences News Headlines

$40.92
+3.14 (+8.31 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$37.49
$41.19
50-Day Range
$32.15
$49.71
52-Week Range
$1.63
$117.54
Volume1.02 million shs
Average Volume5.30 million shs
Market Capitalization$1.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47

Headlines

Cassava Sciences (NASDAQ SAVA) News Headlines Today

SourceHeadline
Cassava Sciences, Inc. (NASDAQ:SAVA) Expected to Announce Earnings of -$0.11 Per ShareCassava Sciences, Inc. (NASDAQ:SAVA) Expected to Announce Earnings of -$0.11 Per Share
americanbankingnews.com - May 13 at 11:24 AM
Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product DevelopmentCaladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development
markets.businessinsider.com - May 12 at 3:11 PM
Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of HealthCassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health
finance.yahoo.com - May 12 at 7:55 AM
Bidens Budget May Boost These 3 BiotechsBiden's Budget May Boost These 3 Biotechs
finance.yahoo.com - May 10 at 4:31 PM
Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s diseaseCassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s disease
markets.businessinsider.com - May 10 at 9:02 AM
Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s diseaseCassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s disease
finance.yahoo.com - May 10 at 9:02 AM
Brokers Offer Predictions for Cassava Sciences, Inc.s FY2022 Earnings (NASDAQ:SAVA)Brokers Offer Predictions for Cassava Sciences, Inc.'s FY2022 Earnings (NASDAQ:SAVA)
americanbankingnews.com - May 6 at 10:13 AM
Were Not Very Worried About Cassava Sciences (NASDAQ:SAVA) Cash Burn RateWe're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
nasdaq.com - May 5 at 6:58 PM
Cassava Sciences (SAVA): Possible Buyout Considerations For The Savvy InvestorCassava Sciences (SAVA): Possible Buyout Considerations For The Savvy Investor
seekingalpha.com - May 5 at 8:58 AM
Cassava Sciences (NASDAQ:SAVA) Shares Gap Down to $42.99Cassava Sciences (NASDAQ:SAVA) Shares Gap Down to $42.99
americanbankingnews.com - May 4 at 11:06 AM
Cassava Sciences (NASDAQ:SAVA) Stock Price Down 6.1%Cassava Sciences (NASDAQ:SAVA) Stock Price Down 6.1%
americanbankingnews.com - May 3 at 12:44 PM
Thinking about trading options or stock in Cassava Sciences, Apple, United Parcel Service, Draftkings, or MicroStrategy?Thinking about trading options or stock in Cassava Sciences, Apple, United Parcel Service, Draftkings, or MicroStrategy?
benzinga.com - April 27 at 3:32 PM
Cassava: Breaking Down B. Riley’s New Bullish CallCassava: Breaking Down B. Riley’s New Bullish Call
finance.yahoo.com - April 27 at 2:00 PM
Cassava Sciences (NASDAQ:SAVA) Shares Gap Up to $41.81Cassava Sciences (NASDAQ:SAVA) Shares Gap Up to $41.81
americanbankingnews.com - April 27 at 11:18 AM
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience ConferenceCassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
finance.yahoo.com - April 27 at 9:00 AM
Cassava Sciences (NASDAQ:SAVA) Research Coverage Started at B. RileyCassava Sciences (NASDAQ:SAVA) Research Coverage Started at B. Riley
americanbankingnews.com - April 27 at 6:30 AM
Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation ForumCassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum
finance.yahoo.com - April 26 at 9:09 AM
Cassava Sciences, Inc. (NASDAQ:SAVA) Expected to Post Earnings of -$0.10 Per ShareCassava Sciences, Inc. (NASDAQ:SAVA) Expected to Post Earnings of -$0.10 Per Share
americanbankingnews.com - April 25 at 4:12 PM
Thinking about trading options or stock in Apple, DermTech, Cassava Sciences, Bilibili, or General Electric?Thinking about trading options or stock in Apple, DermTech, Cassava Sciences, Bilibili, or General Electric?
benzinga.com - April 23 at 12:48 PM
Cassava Sciences Stock at $110 a Share? This Analyst Thinks It’s PossibleCassava Sciences Stock at $110 a Share? This Analyst Thinks It’s Possible
finance.yahoo.com - April 23 at 7:48 AM
Cassava Sciences EPS misses by $0.01; outlookCassava Sciences EPS misses by $0.01; outlook
seekingalpha.com - April 23 at 12:36 AM
BRIEF-Cassava Sciences Reports Q1 2021 Financial Results And Announces Guidance On Clinical Data ReleaseBRIEF-Cassava Sciences Reports Q1 2021 Financial Results And Announces Guidance On Clinical Data Release
msn.com - April 21 at 1:28 PM
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data ReleaseCassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
finance.yahoo.com - April 21 at 8:58 AM
Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?
finance.yahoo.com - March 24 at 12:49 PM
Cassava Sciences Announces Full-year 2020 Financial Results and Business HighlightsCassava Sciences Announces Full-year 2020 Financial Results and Business Highlights
finance.yahoo.com - March 23 at 10:38 AM
Should You Buy Cassava Sciences Stock Now?Should You Buy Cassava Sciences Stock Now?
finance.yahoo.com - March 21 at 7:26 AM
Cassava: A Promising Yet Risky Alzheimer’s Pure PlayCassava: A Promising Yet Risky Alzheimer’s Pure Play
finance.yahoo.com - March 19 at 11:05 PM
Can Rally In Cassava Sciences Stock Continue?Can Rally In Cassava Sciences Stock Continue?
forbes.com - March 19 at 1:04 PM
3 Biotech Stocks to Avoid Right Now3 Biotech Stocks to Avoid Right Now
finance.yahoo.com - March 18 at 8:04 AM
Thinking about trading options or stock in Cassava Sciences, Apple, ADC Therapeutics, Anheuser Busch, or JPMorgan Chase?Thinking about trading options or stock in Cassava Sciences, Apple, ADC Therapeutics, Anheuser Busch, or JPMorgan Chase?
theglobeandmail.com - March 17 at 9:45 AM
A Year Into the COVID-19 Pandemic: 5 Stock WinnersA Year Into the COVID-19 Pandemic: 5 Stock Winners
finance.yahoo.com - March 12 at 3:50 PM
Cassava Sciences (SAVA) Up More Than 600% YTD: Heres WhyCassava Sciences (SAVA) Up More Than 600% YTD: Here's Why
finance.yahoo.com - March 10 at 12:40 PM
Cassava Sciences Announces Pharmaceutical Supply Agreement for SimufilamCassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
finance.yahoo.com - March 9 at 9:43 AM
Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences ConferenceCassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 8 at 12:41 PM
Why Cassava Sciences Stock Skyrocketed 145.1% in FebruaryWhy Cassava Sciences Stock Skyrocketed 145.1% in February
finance.yahoo.com - March 8 at 12:41 PM
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - March 8 at 12:41 PM
Cassava Sciences Can Get To Market Early In AlzheimersCassava Sciences Can Get To Market Early In Alzheimer's
seekingalpha.com - March 6 at 6:29 PM
Cassava: Alzheimer Treatment’s Progress Merits a New Price TargetCassava: Alzheimer Treatment’s Progress Merits a New Price Target
finance.yahoo.com - February 26 at 7:18 PM
Implied Volatility Surging for Cassava Sciences (SAVA) Stock OptionsImplied Volatility Surging for Cassava Sciences (SAVA) Stock Options
nasdaq.com - February 26 at 12:39 PM
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should KnowCassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
nasdaq.com - February 23 at 10:28 PM
Cassava Sciences (SAVA) to Post Q4 Earnings: Whats in Store?Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?
msn.com - February 23 at 12:27 PM
Cassava Sciences to Present at SVB Leerink Global Healthcare ConferenceCassava Sciences to Present at SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 23 at 9:08 AM
Why Cassava Sciencess Stock is Up During Todays SessionWhy Cassava Sciences's Stock is Up During Today's Session
msn.com - February 22 at 2:08 PM
Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimers DiseaseCassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer's Disease
marketwatch.com - February 22 at 2:08 PM
Cassava Sciences jumps 16% on meeting with FDA paving the way for phase 3 study of Alzheimers treatmentCassava Sciences jumps 16% on meeting with FDA paving the way for phase 3 study of Alzheimer's treatment
msn.com - February 22 at 2:08 PM
Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s DiseaseCassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease
finance.yahoo.com - February 22 at 9:06 AM
Cassava: Potential Alzheimer Treatment Opens Door for Lucrative Licensing DealCassava: Potential Alzheimer Treatment Opens Door for Lucrative Licensing Deal
finance.yahoo.com - February 18 at 7:54 PM
Is Cassava Sciences (SAVA) Stock Outpacing Its Medical Peers This Year?Is Cassava Sciences (SAVA) Stock Outpacing Its Medical Peers This Year?
msn.com - February 18 at 1:54 PM
Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should KnowCassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know
msn.com - February 17 at 7:06 PM
Maxim Group Maintains Buy on Cassava Sciences, Raises Price Target to $80Maxim Group Maintains Buy on Cassava Sciences, Raises Price Target to $80
benzinga.com - February 16 at 2:33 PM
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.